Cargando…

Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study

Serum myostatin and indoxyl sulfate (IS) levels increase with kidney function decline and may function as uremic toxins in chronic kidney disease (CKD)-related sarcopenia. Herein, we analyzed the association between serum myostatin and IS levels and sarcopenia in patients with CKD, by performing a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Su Mi, Han, Mi Yeun, Kim, Su Hyun, Cha, Ran Hui, Kang, Seock Hui, Kim, Jun Chul, An, Won Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610577/
https://www.ncbi.nlm.nih.gov/pubmed/36287929
http://dx.doi.org/10.3390/toxins14100660
_version_ 1784819305742860288
author Lee, Su Mi
Han, Mi Yeun
Kim, Su Hyun
Cha, Ran Hui
Kang, Seock Hui
Kim, Jun Chul
An, Won Suk
author_facet Lee, Su Mi
Han, Mi Yeun
Kim, Su Hyun
Cha, Ran Hui
Kang, Seock Hui
Kim, Jun Chul
An, Won Suk
author_sort Lee, Su Mi
collection PubMed
description Serum myostatin and indoxyl sulfate (IS) levels increase with kidney function decline and may function as uremic toxins in chronic kidney disease (CKD)-related sarcopenia. Herein, we analyzed the association between serum myostatin and IS levels and sarcopenia in patients with CKD, by performing a post hoc analysis of baseline data extracted from the RECOVERY study (clinicaltrials.gov: NCT03788252) of 150 patients with CKD. We stratified patients into two groups according to the median value of myostatin (cutoff 4.5 ng/mL) and IS levels (cutoff 0.365 mg/dL). The proportion of patients with sarcopenia was higher in those with high IS levels but lower in those with high myostatin levels. The skeletal muscle mass index (SMI) and handgrip strength (HGS) were significantly lower in patients with high IS levels but significantly higher in patients with high myostatin levels. IS levels showed a negative correlation with glomerular filtration rate (GFR), SMI, and HGS. However, myostatin levels were positively correlated with SMI and HGS, but not with GFR. Sarcopenia was independently associated with age and IS level after adjustment. Increased levels of serum total IS might play a role in sarcopenia, while increased levels of serum myostatin are associated with muscle mass in patients with CKD.
format Online
Article
Text
id pubmed-9610577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96105772022-10-28 Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study Lee, Su Mi Han, Mi Yeun Kim, Su Hyun Cha, Ran Hui Kang, Seock Hui Kim, Jun Chul An, Won Suk Toxins (Basel) Article Serum myostatin and indoxyl sulfate (IS) levels increase with kidney function decline and may function as uremic toxins in chronic kidney disease (CKD)-related sarcopenia. Herein, we analyzed the association between serum myostatin and IS levels and sarcopenia in patients with CKD, by performing a post hoc analysis of baseline data extracted from the RECOVERY study (clinicaltrials.gov: NCT03788252) of 150 patients with CKD. We stratified patients into two groups according to the median value of myostatin (cutoff 4.5 ng/mL) and IS levels (cutoff 0.365 mg/dL). The proportion of patients with sarcopenia was higher in those with high IS levels but lower in those with high myostatin levels. The skeletal muscle mass index (SMI) and handgrip strength (HGS) were significantly lower in patients with high IS levels but significantly higher in patients with high myostatin levels. IS levels showed a negative correlation with glomerular filtration rate (GFR), SMI, and HGS. However, myostatin levels were positively correlated with SMI and HGS, but not with GFR. Sarcopenia was independently associated with age and IS level after adjustment. Increased levels of serum total IS might play a role in sarcopenia, while increased levels of serum myostatin are associated with muscle mass in patients with CKD. MDPI 2022-09-23 /pmc/articles/PMC9610577/ /pubmed/36287929 http://dx.doi.org/10.3390/toxins14100660 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Su Mi
Han, Mi Yeun
Kim, Su Hyun
Cha, Ran Hui
Kang, Seock Hui
Kim, Jun Chul
An, Won Suk
Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
title Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
title_full Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
title_fullStr Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
title_full_unstemmed Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
title_short Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study
title_sort indoxyl sulfate might play a role in sarcopenia, while myostatin is an indicator of muscle mass in patients with chronic kidney disease: analysis from the recovery study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610577/
https://www.ncbi.nlm.nih.gov/pubmed/36287929
http://dx.doi.org/10.3390/toxins14100660
work_keys_str_mv AT leesumi indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy
AT hanmiyeun indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy
AT kimsuhyun indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy
AT charanhui indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy
AT kangseockhui indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy
AT kimjunchul indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy
AT anwonsuk indoxylsulfatemightplayaroleinsarcopeniawhilemyostatinisanindicatorofmusclemassinpatientswithchronickidneydiseaseanalysisfromtherecoverystudy